Press Releases
Lilly Sends Employees to Serve in Vulnerable Communities around the World
First Connecting Hearts Abroad volunteers leave this month to help people in need in Thailand, Peru and Tanzania; more teams deploy later this year Marcio Donatelli, a senior marketing associate with the animal health division of...
Press Releases
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Nivolumab (Opdivo, Nivolumab BMS) for the Treatment of Advanced Squamous Non-Small Cell Lung...
Nivolumab is the first PD-1 immune checkpoint inhibitor to receive a positive opinion from the CHMP in advanced non-small cell lung cancer. Opinion based on overall survival benefit demonstrated in CheckMate -017. CHMP positive opinion marks...
Press Releases
Bristol-Myers Squibb Receives Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatitis C Regimen
Breakthrough Designation for daclatasvir and sofosbuvir combination is supported by the recently presented ALLY-1 trial in patients with advanced cirrhosis or recurrent hepatitis C (HCV) after liver transplant. FDA Designation signifies that high unmet need still...
Press Releases
Eric Stonestreet, of Television’s Hit Comedy, “Modern Family” Joins Forces with Bristol-Myers Squibb to Launch Ready. Raise. Rise.™ to Honor Those Affected by Cancer...
• Ready. Raise. Rise. encourages everyone touched by cancer to create a personalized, virtual flag in honor of a loved one and help raise money for cancer advocacy organizations. • New survey shows lack of...
Press Releases
Lilly and Sanford-Burnham Announce Collaboration to Investigate Immunological Therapies
INDIANAPOLIS, May 14, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Sanford-Burnham Medical Research Institute today announced that they will collaborate to discover and develop immunological therapies. Lilly and Sanford-Burnham, a non-profit medical...
Press Releases
Bristol-Myers Squibb to Present Data at 2015 American Society of Clinical Oncology (ASCO) Annual Meeting that Demonstrate the Promise of its Broad Immuno-Oncology Portfolio...
Pivotal Phase III studies (CheckMate -057 & -017) in both advanced non-squamous and squamous non-small cell lung cancer in which treatment with Opdivo demonstrated superior survival versus chemotherapy with docetaxel in previously-treated patients, to be disclosed. ...
Press Releases
Bristol-Myers Squibb Announces the Early Results of its Cash Tender Offer For Up to $400 Million Aggregate Principal Amount of its Outstanding Debt Securities;...
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that, pursuant to its previously announced cash tender offer for up to $400 million aggregate principal amount (the “tender cap”) of certain of its outstanding debt securities. ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read